Company news

ADMA Biologics Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

August 1, 2023

ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

July 18, 2023

ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023

ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023

May 2, 2023

ADMA Biologics Announces Amendment to Credit Agreement

May 1, 2023

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 22, 2023

ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

March 15, 2023

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

February 7, 2023

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

January 16, 2023

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

December 12, 2022

ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 8, 2022

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

December 6, 2022

ADMA Biologics Announces Proposed Public Offering of Common Stock

December 5, 2022

ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

December 5, 2022

ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

November 8, 2022

ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

November 1, 2022

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

October 30, 2022

ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

August 9, 2022

ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022

August 2, 2022

ADMA Biologics Announces Addition to the Russell 2000® Index

June 20, 2022

ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022

ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022

May 3, 2022

ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

March 31, 2022

ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

March 24, 2022

ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

March 23, 2022

ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

March 20, 2022

ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

March 6, 2022

ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

January 18, 2022

ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC

January 17, 2022

ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

December 20, 2021

ADMA Biologics Provides Update on Global Intellectual Property Portfolio

December 8, 2021

ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors

November 16, 2021

ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC

November 15, 2021

ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

November 9, 2021

ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021

November 2, 2021

ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 24, 2021

ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference

October 21, 2021

ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock

October 20, 2021

ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference

October 18, 2021

ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.

October 17, 2021

ADMA Biologics Announces the Presentation of Real-World Experience in the Management of Respiratory Syncytial Virus (RSV) Presented at IDWeek 2021

October 3, 2021

ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021

September 30, 2021

ADMA Biologics to Virtually Participate in the Cantor Healthcare Conference

September 22, 2021

ADMA Biologics Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations

September 7, 2021

ADMA Biologics to Virtually Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

September 1, 2021

ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN

August 15, 2021

ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

August 10, 2021

ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System

August 9, 2021

ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®

August 8, 2021

ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021

August 3, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.